Journal of Inherited Metabolic Disease

, Volume 30, Issue 4, pp 556–562 | Cite as

Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia

Newborn Screening

Summary

In recent years several studies on tetrahydrobiopterin (BH4)-responsive phenylalanine hydroxylase (PAH) deficiency have been published. The molecular mechanisms of BH4 responsiveness are not conclusively understood, but there is evidence that BH4 responsiveness in hyperphenylalaninaemia (HPA) depends on the patient’s genotype and residual PAH activity. As a BH4 preparation will soon obtain marketing approval as an alternative treatment for phenylketonuria (PKU), it is particularly important to evaluate this treatment and to define criteria to identify patients with a potential benefit from it. Most of the patients found to be BH4-responsive suffered from mild PKU or mild hyperphenylalaninaemia (MHP) and some of these would not be treated at all in many countries. Of patients with moderate and classic forms of PKU, only a few were classified as responders and the clinical significance of the effect size may be small.

Keywords

Phenylketonuria Phenylalanine Hydroxylase Medical Research Council Working Party Mild Hyperphenylalaninaemia Phenylalanine Hydroxylase Deficiency 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abadie V, Berthelot J, Feillet F, et al (2005) Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Arch Pédiatr 12: 594–601.PubMedCrossRefGoogle Scholar
  2. American Academy of Pediatrics (2001) Committee on Genetics. Pediatrics 107: 427–428.CrossRefGoogle Scholar
  3. Bélanger-Quintana A, García MJ, Castro M, et al (2005) Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Genet Metab 86: S61–66.PubMedCrossRefGoogle Scholar
  4. Bernegger C, Blau N (2002) High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002. Mol Genet Metab 77: 304–313.PubMedCrossRefGoogle Scholar
  5. Blaskovics ME, Schaeffler GE, Hack S (1974) Phenylalaninemia: differential diagnosis. Arch Dis Child 49: 835–843.PubMedCrossRefGoogle Scholar
  6. Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ (1996) Intellectual development of the patients of the German collaborative study of children treated for phenylketonuria. Eur J Pediatr 155: S33–38.PubMedCrossRefGoogle Scholar
  7. Blau N (2004) BIOPKU: International Database of Patients and Mutations Causing Tetrahydrobiopterin-responsive HPA/PKU, 2004. Retrieved from <http://www.bh4.org> 19.05.2007.
  8. Blau N (2006) Differenzialdiagnose der Hyperphenylalaninämien. Screening auf angeborene Stoffwechselkrankheiten. Kinder- und Jugendmedizin 6: 225–232.Google Scholar
  9. Blau N, Erlandsen H (2004) The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 82: 101–111.PubMedCrossRefGoogle Scholar
  10. Burgard P, Bremer HJ, Bührdel P, et al (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 158: 46–54.PubMedCrossRefGoogle Scholar
  11. Desviat LR, Perez B, Belanger-Quintana A, et al (2004) Tetrahydrobiopterin responsiveness: results of the BH4 loading in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab 83: 157–162.PubMedCrossRefGoogle Scholar
  12. Erlandsen H (2006) Molecular mechanisms of tetrahydrobiopterin-responsiveness. In: Blau N, ed. PKU and BH4, Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft, 376–400.Google Scholar
  13. Erlandsen H, Stevens RC (1999) The structural basis of phenylketonuria. Mol Genet Metab 68: 103–125.PubMedCrossRefGoogle Scholar
  14. Erlandsen H, Fusetti F, Martinez A, Hough E, Flatmark T, Stevens RC (1997) Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria. Nat Struct Biol 4: 995–1000.PubMedCrossRefGoogle Scholar
  15. Fiege B, Ballhausen D, Kierat L, et al (2004) Plasma tetrahydrobiopterin and its pharmacokinetics following oral administration. Mol Genet Metab 81: 45–51.PubMedCrossRefGoogle Scholar
  16. Fiori L, Fiege B, Riva E, Giovannini M (2005) Incidence of BH4-responsiveness in phenylalanine-hydroxylase deficient Italian patients. Mol Genet Metab 86: S67–74.PubMedCrossRefGoogle Scholar
  17. Fusetti F, Erlandsen H, Flatmark T, Stevens RC (1998) Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J Biol Chem 273: 16962–16967.PubMedCrossRefGoogle Scholar
  18. Güttler F (1980) Hyperphenylalaninemia: diagnosis and classification of the various types of phenylalanine hydroxylase deficiency. Acta Paediatr Scand 280 (Supplement): 1–80.Google Scholar
  19. Güttler F, Azen C, Guldberg P, et al (1999) Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: Report from the Maternal Phenylketonuria Collaborative Study. Pediatrics 104: 258–262.PubMedCrossRefGoogle Scholar
  20. Güttler F, Guldberg P (2000) Mutation analysis anticipates dietary requirements in phenylketonuria. Eur J Pediatr 159 (Supplement): S150–S153.PubMedCrossRefGoogle Scholar
  21. Guldberg P, Rey F, Zschocke J, et al (1998) A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63: 71–79.PubMedCrossRefGoogle Scholar
  22. Hennermann JB, Bührer C, Blau N, Vetter B, Mönch E (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 86: S86–90.PubMedCrossRefGoogle Scholar
  23. Hoffmann GF, Machill G (1994) 25 Jahre Neugeborenenscreening auf angeborene Stoffwechselstörungen in Deutschland. Monatsschr Kinderheilkd 142: 857–862.Google Scholar
  24. Koch R, Moseley K, Guttler F (2005) Tetrahydrobiopterin and maternal PKU. Mol Genet Metab 86: S139–141.PubMedCrossRefGoogle Scholar
  25. Kure S, Hou DC, Ohura T, et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135: 375–378.PubMedCrossRefGoogle Scholar
  26. Lambruschini N, Perez-Duenaz B, Vilaseca MA, et al (2005) Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 86: S54–S60.PubMedCrossRefGoogle Scholar
  27. Leitlinien Kinderheilkunde und Jugendmedizin (1997) No. 027/002. Phenylketonurie, Maternale Hyperphenylalaninämie, Tetrahydrobiopterin (BH4)–Stoffwechselstörungen: www.awmf-online.de.
  28. Leuzzi V, Carducci C, Chiarotti F, Artiola C, Giovanniello T, Antonozzi I (2006) The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. J Inherit Metab Dis 29: 38–46.PubMedCrossRefGoogle Scholar
  29. Lindner M, Haas D, Zschocke J, Burgard P (2001) Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol Genet Metab 73: 104–106.PubMedCrossRefGoogle Scholar
  30. Lindner M, Steinfeld R, Burgard P, Schulze A, Mayatepek E, Zschocke J (2003) Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 21(4): 400.PubMedCrossRefGoogle Scholar
  31. Lutz P, Schmidt H, Frey G, Bickel H (1982) Standardized loading test with protein for the differentiation of phenylketonuria from hyperphenylalaninemia. J Inherit Metab Dis 5: 29–35.PubMedCrossRefGoogle Scholar
  32. Lutz P, Schmidt H, Batzler U (1990) Study design and description of patients. Eur J Pediatr 149(Supplement 1): 5–12.CrossRefGoogle Scholar
  33. MacDonald A (2000) Diet and compliance in phenylketonuria. Eur J Pediatr 159: S136–141.PubMedCrossRefGoogle Scholar
  34. MacDonald A, Harris G, Rylance G, Asplin DA, Booth IW (1997) Abnormal feeding behaviour in phenylketonuria. J Hum Nutr Diet 10: 163–170.CrossRefGoogle Scholar
  35. Matalon R, Koch R, Michals-Matalon K, et al (2004) Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 6(1): 27–32.PubMedCrossRefGoogle Scholar
  36. Matalon R, Michals-Matalon K, Koch R, Grady J, Tyring S, Stevens RC (2005) Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab 86: S17–21.PubMedCrossRefGoogle Scholar
  37. Medical Research Council Working Party on Phenylketonuria (1993) Recommendations on the dietary management of phenylketonuria. Arch Dis Child 68: 426–427.Google Scholar
  38. Muntau A, Roschinger W, Habich M, et al (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylkentonuria. N Engl J Med 347: 2122–2132.PubMedCrossRefGoogle Scholar
  39. Muntau AC, Gersting SW (2006) Treatment of patients with tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. In: Blau N, ed. PKU and BH4, Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft, 104–119.Google Scholar
  40. National Institutes of Health Consensus Developement Conference Statement (2001) Phenylketonuria: screening and management. 2000 Oct. 16–18. Pediatrics 108: 972–982.CrossRefGoogle Scholar
  41. Niederwieser A, Matasovic A, Staudenmann W, Wang M, Curtius HC (1982) Screening for tetrahydrobiopterin deficiency. In: Wachter H, Curtius HC, Pfleiderer W, eds. Biochemical and Clinical Aspects of Pteridines, vol. 1. Berlin: De Gruyter, 293–306.Google Scholar
  42. Niederwieser A, Ponzone A, Curtius HC (1985) Differential diagnosis of tetrahydrobiopterin deficiency. J Inherit Metab Dis 8(Supplement 1): 34–38.PubMedCrossRefGoogle Scholar
  43. Perez-Duenas B, Vilaseca MA, Mas A, et al (2004) Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin Biochem 37: 1083–1090.PubMedCrossRefGoogle Scholar
  44. Scriver CR, Kaufman S (2001) Hyperphenylalaninemias: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667–1724.Google Scholar
  45. Shintaku H, Kure S, Ohura T, et al (2003) Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res 55: 1–6.Google Scholar
  46. Trefz F, Blau N (2003) Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112: 1566–1569.PubMedGoogle Scholar
  47. Walter JH, White FJ, Hall SK, et al (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360: 55–57.PubMedCrossRefGoogle Scholar
  48. Weglage J, Funders B, Ullrich K, Rupp A, Schmidt E (1996) Psychosocial aspects in phenylketonuria. Eur J Pediatr 155: S101–104.PubMedCrossRefGoogle Scholar
  49. Zurflüh MR, Fiori L, Fiege B, et al (2006) Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. J Inherit Metab Dis 29(6): 725–731.PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  • G. Gramer
    • 1
    • 2
  • P. Burgard
    • 1
    • 2
  • S. F. Garbade
    • 1
    • 2
  • M. Lindner
    • 1
    • 2
    • 3
  1. 1.Zentrum für Kinder- und JugendmedizinHeidelbergGermany
  2. 2.METABNET: Netzwerk für im Neugeborenen-Screening erfassbare seltene genetische StoffwechselstörungenHeidelbergGermany
  3. 3.Stoffwechselzentrum Heidelberg, Sektion für angeborene StoffwechselkrankheitenZentrum für Kinder- und JugendmedizinHeidelbergGermany

Personalised recommendations